HER-2/neu oncogene protein and prognosis in breast cancer.
about
Translating pharmacogenomics: challenges on the road to the clinicElevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomasBreast cancer chemoprevention: old and new approachesTissue microarrays for rapid linking of molecular changes to clinical endpointsStatistical analysis of array expression data as applied to the problem of tamoxifen resistance.The relationship between prognostic and predictive factors in the management of breast cancer.HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expressionEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesHER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.Predicting the clinical status of human breast cancer by using gene expression profiles.Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.HER2: the neu prognostic marker for breast cancer.Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes.Testing for HER2 in Breast Cancer: A Continuing Evolution.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.Guideline conformity treatment in young women with early-onset breast cancer in GermanyMolecular biology in the diagnosis and prognosis of solid and lymphoid tumors.Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cellsRadiotherapy update.Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters.Efficacy and tolerability of lapatinib in the management of breast cancerRole of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.Prognostic significance of c-erbB-2 expression in node negative breast cancerPrognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer.Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpressionc-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.c-erbB-2 oncoprotein expression in primary and advanced breast cancerThe relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancerStudy of the biological and prognostic significance of the antigen CaMBr8 on breast carcinoma.Trastuzumab: updated mechanisms of action and resistance in breast cancerIn Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast CancerSoluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancererbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicatorsPrognostic factors and recurrence in breast cancer: experience at the national cancer institute of MexicoAssociations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.Significance of Her-2/neu protein over expression in Indian breast cancer patientsBreast and prostate cancer.
P2860
Q21092371-20C7075C-5987-4F28-A241-72C5E3A20BEDQ24559979-63B06DCA-D886-46E1-9C0C-DE2AAFE24CC0Q27693259-5F2E18EF-BA2D-46BB-A14D-CAFA263DE4D3Q28365753-314A3811-9D5A-4BCE-AB60-3EC7D440D90AQ30559389-1F946458-BAA0-474B-BC81-7723AF202DB4Q33538455-368B82FD-FC44-4D40-BAF4-43A20C69C1C4Q33690070-D6356F52-CC08-4247-A807-1D56FA1B7857Q33691211-DADDA433-9AF4-4F0E-9E5E-3D091D5A2C17Q33737278-3D435B82-5006-4273-BC6C-8C396B4F0675Q33816025-4E40CFB5-C5C2-4A16-82E3-1DEBC498FFB9Q33944626-AB2FAA6F-F8F0-428B-BA34-060C45A6BBDCQ33995239-F106EC48-3C4A-4A30-9666-A7F2F3067B89Q34248406-CF18606F-B015-4F6C-AB1A-898F1ECB0A31Q34375924-51C9485D-3057-43C2-8804-D860BFE413ECQ34424285-75FC0D83-77AC-4835-B902-DDF62BC0095EQ34713799-0145BF81-C45D-4D5C-AF10-9345BF05C12EQ35066948-A4EBC365-C6DA-4272-834F-6DFF6CA61522Q35367195-5447DBF3-0AAB-49FA-B856-EE30257E351CQ35604651-EC210C30-9A46-4B9C-A1B5-4693C3854D64Q35742199-3CF431B8-63D6-47B4-80E1-555A66E98A9AQ35822198-22467A02-DED2-4FD7-989D-47C1BE7FF2C2Q35831370-B34A7D3F-EFC2-4AAB-A2FE-409CEC839863Q35835926-3F4DA89F-61E9-4C8F-823A-0FADDC558292Q35839056-E3F34663-6C1C-4377-B478-6618DFD7FAC5Q35976044-08CA427D-8DCF-47F6-A65F-C8E5412D18F2Q35976618-44FEDC90-858C-498B-81DD-A58B11A61CC7Q35981979-3DD8C6B1-A306-42CB-841C-7EB147243968Q35983237-0BBC5045-CDC0-4E10-8E70-8A473394FE0EQ35983286-00441F2F-ADE2-47B1-A28D-88EDFD1C9BB7Q35983317-35514B24-AF20-4DD9-8504-AA17926881BEQ35993619-78FE4BE3-7E47-4D7C-B2E3-897A2A717FCFQ36036437-8C4A12B8-E575-4A8E-ABD1-ED7976D58AC6Q36061810-E1A2706D-440D-4312-95C5-8BB9C93466EDQ36079736-94F7EACE-0A1E-48AC-BBAD-FDA9BD286D2FQ36080272-A85A77AF-5EC9-4546-BD4C-914E02145ED1Q36081213-63863FE9-7FCC-4D63-880D-54A9C2FF61FEQ36102243-5097A852-5A46-43BB-BF43-868981AEA300Q36138971-87417974-4B64-4601-89EC-FC5D54CE212CQ36261607-9796B120-001B-4194-9EF6-7C7B2DB9F511Q36265549-607B0CD1-78B9-407F-A758-EAF120F6D86A
P2860
HER-2/neu oncogene protein and prognosis in breast cancer.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
HER-2/neu oncogene protein and prognosis in breast cancer.
@en
type
label
HER-2/neu oncogene protein and prognosis in breast cancer.
@en
prefLabel
HER-2/neu oncogene protein and prognosis in breast cancer.
@en
P2093
P1476
HER-2/neu oncogene protein and prognosis in breast cancer.
@en
P2093
A K Tandon
G C Chamness
W L McGuire
P304
P356
10.1200/JCO.1989.7.8.1120
P407
P577
1989-08-01T00:00:00Z